CLINICAL TRIALS MENU

Clinical Trials - Complete NMCC List

The listing of open clinical trials below is primarily intended for medical oncologists, nurses and clinical trial coordinators. If you are a patient, we encourage you to discuss with your oncologist whether there are any clinical trials that might be of benefit to you. In the near future, we hope to have plain language descriptions of these clinical trials for use by patients.

OPEN CLINICAL TRIALS AT NMCC (#=51) - Updated March 29, 2018
Category Trial # Description
Breast Adjuvant ECOG-ACRIN EA1131 A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Breast Adjuvant SWOG S1207 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
Breast Adjuvant Alliance A011502 A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
Breast Adjuvant NSABP B-51/RTOG 1304 A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Breast Adjuvant SWOG S1418/BR006 A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy
Breast Adjuvant Alliance Foundation Trials AFT-05, ABCSG 42, BIG 14-03 PALLAS: PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer
Breast Advanced SWOG S1416 Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
Breast Advanced ECOG E2112 A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer
Breast Advanced NRG-BR002 A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Breast Advanced Novartis CLEE011A2404 COMPLEEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
GI Pancreatic Advanced SWOG S1513 Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
GU Prostate Adjuvan Advantagene PrTK03 A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer
Head And Neck Adjuvant ECOG-ACRIN EA3132 Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Ill Defined SWOG S1609 A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the anaplastic Lymphoma Kinase (ALK) Fusion Protein
Lung NSCLC Adjuvant ECOG-ACRIN E4512 A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the anaplastic Lymphoma Kinase (ALK) Fusion Protein
Lung NSCLC Adjuvant Alliance A151216 Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Lung NSCLC Adjuvant Alliance A081105 Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Lung NSCLC Advanced RTOG 1306 A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
Lung NSCLC Advanced SWOG S1403 A Randomized Phase II/III Trial of Afatinib plus Cetuximab versus Afatinib Alone in Treatment-Na
Lung NSCLC Advanced Bristol-Myers Squibb CA209568 A Study of Nivolumab in Combination with Ipilimumab (part 1); and Nivolumab plus Ipilimumab in Combination with Chemotherapy vs. Chemotherapy alone (part 2) as First Line Therapy in stage IV Non-Small Cell Lung Cancer (NSCLC)
Lung Other SWOG S1400 Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Lung SCLC Advanced S1400G A Phase II Study of Talazoparib (BMN 673) in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
Lung SCLC Advanced SWOG S1400I A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Molecular Genetics INST 96144 City of Hope Molecular Genetics Studies of Cancer Patients and Their Relatives
Mutation Based ECOG-ACRIN EAY131-A Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
Mutation Based ECOG-ACRIN EAY131-Y Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol Y: AZD5363 in Patients with Tumors with AKT Mutations
Mutation Based ECOG-ACRIN EAY131-L Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
Mutation Based ECOG-ACRIN EAY131-C2 Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
Mutation Based ECOG-ACRIN EAY131-J Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification
Mutation Based ECOG-ACRIN EAY131-W Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol W: Phase II Study of AZD4547 in Patients with Tumors with Aberrations in the FGFR Pathway
Mutation Based ECOG-ACRIN EAY131-S2 Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations
Mutation Based ECOG-ACRIN EAY131-Z1 Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
Mutation Based ECOG-ACRIN EAY131-C1 Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
Mutation Based ECOG-ACRIN EAY131-M Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
Mutation Based ECOG-ACRIN EAY131-Z1B Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification and Rb Protein Expression by IHC
Mutation Based ECOG-ACRIN EAY131-V Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
Mutation Based ECOG-ACRIN EAY131-T Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
Mutation Based ECOG-ACRIN EAY131-E Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
Mutation Based ECOG-ACRIN EAY131-X Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol X: Phase II Study of Dasatinib in Patients with Tumors with DDR2 Mutations
Mutation Based ECOG-ACRIN EAY131-Z1E LOXO-101 in Patients with Tumors with NTRK Fusions
Mutation Based ECOG-ACRIN EAY131-Z1A Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol Z1A: Binimetinib in Patients with Tumors (Other Than Melanoma) with NRAS Mutations
Mutation Based ECOG-ACRIN EAY131-U Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol U: VS-6063 (defactinib) in Patients with Tumors with NF2 Loss
Mutation Based ECOG-ACRIN EAY131-Z1I Phase II Study of AZD1775 in Patients with Tumors Containing BRCA1 and BRCA2 Mutations
Mutation Based ECOG-ACRIN EAY131-Z1D Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol Z1D: Nivolumab in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer)
Mutation Based ECOG-ACRIN EAY131-B Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol B: Phase II Study of Afatinib in Patients with Tumors with HER2 Activating Mutations
Skin Melanoma Advanced ECOG-ACRIN EA6134 A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
Skin Melanoma Advanced ECOG-ACRIN EA6141 Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Solid Tumors Other ECOG-ACRIN EAY131-H Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with tumors with BRAF V600E or V600K mutations (excluding melanoma and thyroid cancer)
Solid Tumors Other ECOG-ACRIN EAY131-F Molecular Analysis for Therapy Choice(MATCH)Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations
Solid Tumors Other ECOG-ACRIN EAY131-R Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol R: Phase II Study of Trametinib in patients with BRAF fusions, or with non-V600E, nonV600K BRAF mutations
Solid Tumors Other ECOG-ACRIN EAY131-G Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol G: Phase II study of Crizotinib in patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer)

Your Strongest Ally to Conquer Cancer

Pin It on Pinterest

Share This